10:04 AM EST, 03/05/2024 (MT Newswires) -- Baxter International ( BAX ) is exploring the potential sale of its Kidney Care business with "select private equity investors," the health care company said late Monday in a regulatory filing.

Baxter said while there has been no final decision about a sale, it continues to expect completing some form of a separation of the Kidney Care business, such as the 2023 planned spinoff of it as a stand-alone company to be named Vantive, from the primary company during H2.

The company did not identify any of the private equity firms interested in a potential acquisition of the Kidney Care business in its regulatory filing.

Baxter shares were nearly 3% higher in recent early Tuesday trading.

Price: 43.66, Change: +1.16, Percent Change: +2.73